Month: December 2015

In today’s article, we will be covering a very hot topic in the E&P sector right now: liquidity. More specifically, how you can use Sentieo to quickly find out about a company’s credit facility as well as any restrictive indentures that might be out there limiting the amount of debt that a company can take on.

Most E&P companies are financed with some combination of equity and debt. Often times, these companies will supplement their equity and debt financing with revolving lines of credit that can come in two forms: asset-based or a more traditional facility based on earnings.

Asset based revolving lines of credit are tied to the present value of their proved reserves (reserves with a high degree of certainty that these resources can be extracted from the ground) and are typically assigned to non-investment grade companies since they do not have the creditworthiness to have a facility that is simply governed by earnings. The amount of borrowing capacity on these reserve based lending credit facilities is typically reassessed twice a year, once in the spring and once in fall. Read More

The pharma CEO Martin Shkreli has been attracting attention lately after taking a very large position in KaloBios Pharmaceuticals. After Shkreli made his initial investment, the stock has risen roughly 40-fold. One of the more interesting documents that I found was the Retrophin 8-K filed on August 17, 2015 (EDGAR, snt.io). Shkreli’s former employer seemed a little unhappy with its former CEO, accusing him of:

“repeatedly breaching his duty of loyalty to Retrophin”

being the “paradigm faithless servant”

using “his control over Retrophin to enrich himself, and to pay off claims of MSMB investors (who he had defrauded)”

diverting “47,610 Retrophin shares for the benefit of himself and his MSMB Funds, resulting in a benefit to him and to them of more than $4.5 million (at current market prices)”

About Sentieo

DISCLAIMER

Nothing on this website should be considered investment advice. We do not make recommendations (long or short) in any securities. We do not express opinions as to whether any company's accounting practices are in violation of SEC, GAAP, IFRS or other rules/regulations.